Fort Worth, TXNCT07540572Now EnrollingIRB Ready

ER+, HER 2- Breast Cancer Clinical Trial in Fort Worth, TX

Access cutting-edge er+, her 2- breast cancer treatment through this clinical trial at a research site in Fort Worth. Study-provided care at no cost to qualified participants.

Sponsored by IDEAYA Biosciences

Quick Self-Assessment

See if you qualify for this Fort Worth location

Preparing your pre-screening questions…

Expert Care in Fort Worth

Access er+, her 2- breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related er+, her 2- breast cancer treatment provided free

Apply for This Fort Worth Location

Check if you qualify for this er+, her 2- breast cancer clinical trial in Fort Worth, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fort Worth

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fort Worth site if eligible
  4. 4Begin participation

About This ER+, HER 2- Breast Cancer Study in Fort Worth

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic ER+, HER2- breast cancer.

Sponsor: IDEAYA Biosciences

Who Can Participate

Inclusion Criteria

Archival Tissue sample for testing
Part 1A - Participants with advanced or metastatic ER+, HER2- breast cancer, NSCLC, CRPC, and MSS colorectal adenocarcinoma who have progressed on/after at least one line of standard of care therapy or are intolerant to additional effective therapies.
Parts 1B, 2A and 2B: Participants with ER+, HER2- breast cancer who have progressed after at least 1 prior line of treatment with an endocrine therapy and a CDK4/6 inhibitor
Female participants with ER+, HER2- breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
Female participants of nonchildbearing potential with ER+, HER2- breast cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age \<60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
Have adequate bone marrow, renal and liver function.
Life expectancy of \>3 months
Able to safely administer and retain orally administered study treatment
Able to comply with contraceptive/barrier requirements Key

Exclusion Criteria

Known symptomatic brain metastases or leptomeningeal metastasis
Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
Have active liver or biliary disease.
Have active, uncontrolled bacterial, fungal, or viral infection
Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
Prior irradiation to \>25% of the bone marrow.
Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 \& 2) or fulvestrant/excipients or components (Part 2 only)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fort Worth?

Yes, this clinical trial (NCT07540572) has an active research site in Fort Worth, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

ER+, HER 2- Breast Cancer Treatment Options in Fort Worth, TX

If you're searching for er+, her 2- breast cancer treatment options in Fort Worth, TX, this clinical trial (NCT07540572) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fort Worth research site is actively enrolling participants for this clinical trial. You'll receive care from experienced er+, her 2- breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all er+, her 2- breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Fort Worth, TX

See all breast cancer clinical trials recruiting in Fort Worth — not just this study.

Browse Breast Cancer Trials in Fort Worth →

Browse More Trials by Condition

Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Fort Worth?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fort Worth, TX